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Attention-deficit/hyperactivity disorder (ADHD) is often treated with psychostimulants. 
Psychostimulants’ adverse effects on body mass index standard deviation score (BMI-sds) and height 
in children/adolescents with ADHD have been reported. However, literature is inconsistent, and it is 
unclear whether the observed effects are dosage- and/or BMI dependent. Therefore, the aim of this 
retrospective observational study is to evaluate the influence of psychostimulants on BMI-sds and 
height-sds in a pediatric cohort with ADHD from an outpatient clinic, and to study the correlation 
between psychostimulant dosage and BMI-sds and height-sds change.  
 
Method 
Participants ≤18 years diagnosed with ADHD who started with psychostimulants (methylphenidate) 
were studied. Changes in BMI-sds and height-sds over an 18 month treatment period were assessed 
in subgroups according to baseline BMI-sds, gender, and age. Furthermore, correlations between 
BMI-sds, height-sds and psychostimulant dose were studied.  
 
Results 
In total 298 participants (median age 9.8 years, height-sds 0.0, BMI-sds 0.5, psychostimulant dosage 
0.5 (0.2-1.4) mg/kg/day) were analyzed, with an underweight, overweight and obesity prevalence of 
5%, 21% and 7%, respectively. After 18 months of treatment a significant decline in BMI-sds (-0.4) 
and height-sds (-0.2) was observed. These effects were consistent in all subgroups except for no 
change in BMI-sds in the underweight subgroup and no change in height-sds in the overweight 
subgroup. Medication dosage was weakly correlated with change in BMI-sds (r= -0.3 (-0.9 - +0.5); 
p<0.01), and height-sds (r=-0.2 (-0.4 - -0.1); p=0.01).  
 
Conclusion  
After 18 months of psychostimulant treatment, a significant decline in BMI-sds and height-sds was 
observed. However, the correlation with psychostimulant dosage was weak, and the decline was not 
observed in all subgroups. Therefore, further studies on the etiology of BMI-change are warranted, 








Attention-deficit/hyperactivity disorder (ADHD) is characterized by a pattern of inattention, 
hyperactivity, and impulsivity with an early onset in life. A distinction is made between a 
predominantly inattentive type and a predominantly combined type of ADHD. The worldwide 
prevalence of ADHD in pediatric populations is estimated between 3 and 7% [1-4]. ADHD is seen in all 
weight categories as in the general population, although a recent review and meta-analysis show a 
40% higher prevalence of obesity in children/adolescents with ADHD compared to healthy 
children/adolescents [5]. This observation might be explained by differences/variation in expression 
of ADHD symptoms. It has been suggested that impulsive and inattentive components of ADHD could 
lead to irregular and dysregulated eating patterns leading to a higher risk of overweight/obesity [5-
8]. In addition, it has been described that children with ADHD spend less time practicing sport and 
spend more time watching TV [9]. The (momentary) hyperactivity could therefore be not enough to 
reduce the risk of overweight/obesity. Consequently, body mass index (BMI) might be a reflection of 
the variability of ADHD symptoms. 
Psychostimulants are frequently used in the treatment of AHDH and have been associated with 
weight loss due to their known negative effect on appetite [10-16]. However, a decrease in body 
weight is not observed in all studies [5,17-19], and some even reported a higher obesity prevalence 
in those under psychostimulant treatment [20,21]. Psychostimulants have also been associated with 
the reduction of growth velocity and target height [22]. Although literature is inconsistent, some 
studies report growth suppression during treatment [14,23-28], while others did not [18,26,29]. On 
the contrary, it has been suggested that the effect of psychostimulants on height attenuates over 
time and is therefore of no clinical significance [24-28]. 
From the foregoing, it appears that there is no consistency in the association between 
psychostimulant treatment and weight reduction and/or growth suppression in pediatric populations 
with ADHD. In addition, it seems unclear whether medication dosage is influencing the association 
and whether there are differences between BMI-categories. Therefore, the aim of this retrospective 
observational study is to evaluate the influence of psychostimulants on BMI standard deviation score 
(BMI-sds) and height-sds over an 18 month treatment period, in a pediatric cohort with ADHD visiting 
an outpatient clinic. In addition, the correlation between psychostimulant dosage and BMI-sds and 
height-sds change is evaluated. 
 
Method 
Study design and subjects 
This retrospective observational study was approved by the Medical Ethical Committee of the St. 
Antonius Hospital, Nieuwegein/Utrecht, the Netherlands (Z16.059). As the data were obtained from 
routine clinical care and anonymized, written informed consent was not required. All patients who 
visited the pediatric outpatient clinic of the St. Antonius Hospital between January 2008 and July 
2016 were screened for the diagnosis treatment combination code (DBC-code) “ADHD”. Patients 
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were included if they were aged ≤18 years, diagnosed with ADHD, and started with psychostimulants 
(methylphenidate) for the first time, and did not use any additional psychiatric medication. 
Measurements 
A diagnosis of ADHD was established by a psychologist and/or pediatrician based on criteria of the 
Diagnostic and Statistical Manual (DSM) IV/5 [30,31], using questionnaires and observations by care 
givers and teachers. A distinction was made between the predominantly inattentive and 
predominantly combined type of ADHD. Baseline (T=0) was defined as the start of psychostimulant 
treatment, which was titrated and (as needed) adjusted according to national guidelines, with a 
maximum of 2mg/kg/day [32,33].  
Collected baseline data were as follows: date of birth, gender, type of disease (i.e., predominantly 
inattentive, predominantly combined), date of methylphenidate start, type of methylphenidate (i.e., 
immediate or sustained release), medication dosage (mg/kg/day), and weight and height. 
Participants with incomplete data at baseline were excluded. Data gathered up to 18 months after 
treatment start were as follows: date of visit, type of methylphenidate, medication dosage, and 
weight and height. Since participants did not visit the pediatric outpatient clinic at predetermined 
time points, a window was created to define the time of visit at T=18 months (i.e., day 540, range 
480-600 days). Participants were excluded from analysis if the follow-up visit took place outside the 
defined time window or if data at 18 months were incomplete. In addition data after 6 (day 180, 
range 120-240) and 12 months (day 360, range 300-420) of psychostimulant treatment were 
gathered.  
Weight and height were measured using a digital scale (Seca, Hamburg, Germany) with an accuracy 
of 0.05kg and a digital stadiometer with a precision of 0.1cm (DGI 250D, De Grood, Nijmegen, the 
Netherlands), respectively. BMI and the corresponding age and gender adjusted BMI-sds and height-
sds, were calculated according to national growth charts using the TNO growth calculator for 
professionals [34] Participants were classified into four subgroups defined by baseline BMI-sds i.e. 
that is underweight (BMI-sds ≤-1.1), normal weight (BMI-sds >-1.1-≤1.1), overweight (BMI-sds >1.1 
≤2.3), and obesity (BMI-sds >2.3). In addition, participants were classified into children (≤10 years) 
and adolescents (>10 years).  
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics, version 24 (IBM SPSS Statistics, Chicago, 
IL, USA). Anticipating that the number of participants in the underweight and obese subgroup could 
be limited, all data were reported as median with range for continuous data or as frequencies with 
percentage for categorical data. Differences between the BMI-subgroups were compared using the 
Kruskal-wallis test for continuous data, and the chi squared test for dichotomous data. In addition, 
comparisons between males versus. females and children versus adolescents were performed using 
the Student’s t test. Differences in BMI-sds, height-sds, and psychostimulant dosage between T=0 
and T=18 were analyzed using the paired t-test/Wilcoxon signed-rank test and were conducted for all 
participants and separately for the subgroups.  
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Finally, a multivariable linear regression analysis was conducted to assess the influence of 
psychostimulant dosage on both BMI-sds and height-sds change. Potential confounders (i.e., age, 
gender, type of disease, type of methylphenidate, and baseline BMI-sds) were retained in the final 
regression model if they influenced the coefficient of interest with more than 10%. All results were 
considered significant at a α-level of 5%.  
 
Results 
Figure 1 shows that 1294 patients were screened for inclusion. A total of 558 participants were 
included, of which 298 were analysed. Characteristics of participants excluded for analysis were not 
significantly different from participants analyzed (Supplementary Table 1). 
Figure 1. Flowchart of the study population
 
Table 1 shows the baseline demographics of participants, who were primarily boys (72%). Five 
percent of the participants were classified as underweight, 66% as normal weight, 21% as 
overweight, and 7% as obese. The BMI-subgroups differed significantly in height-sds. Overweight and 
obese participants had a significant higher height-sds in comparison with underweight (p=0.04, 
p=0.04), and normal weight (p=0.01, p=0.04) participants. The predominantly combined type of 
ADHD was diagnosed in 65% and the predominantly inattentive type in 35% of the participants. In 
79%, immediate release methylphenidate was first prescribed. The BMI-subgroups differed 
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significantly in medication dosage (mg/kg/day), as overweight participants received a significantly 
lower medication dosage in comparison with underweight and normal weight participants (p<0.01, 
p=0.01).  
Table 1. Demographics of all participants (n=298), and of BMI-subgroups  
 All n=298 UW n=16 NW n=198 OW n=62 O n=22 Pvalue 











Male n (%) 215 (72) 9 (56) 144 (73) 43 (69) 19 (86) 0.21 





































5.9 (3.3-9.5) 0.58 






























2.9 (2.4-4.5) <0.01 
Type disease n (%)     0.06 
Combined 195 (65) 7 (44) 137 (69) 35 (56) 16 (73)  
Inattentive 103 (35) 9 (56) 61 (31) 27 (44) 6 (27)  
Methylphenidate n (%)     0.74 
IR  235 (79) 12 (75) 154 (78) 52 (84) 17 (77)  
SR  63 (21) 4 (25) 44 (22) 10 (16) 5 (23)  





0.6 (0.4-1.1) 0.6 (0.5-1.4) 0.5 (0.2-
1.0) 
0.5 (0.2-1.0) 0.02 
Data presented as number (%) or median with range. UW = underweight, NW = normal weight, OW = 
overweight, O = Obesity. BMI = body mass index, sds = standard deviation score, IR= immediate 
release, SR = sustained release. P-values for Kruskal-wallis test (continuous data) and χ2 test 
(categorical data). 
Males were significantly more often diagnosed with the predominantly combined type of ADHD in 
comparison with females (71% vs. 52%; p<0.01). No differences were observed in anthropometric 
measurements except for height velocity which was significantly lower in females (6.5 vs. 5.2; 
p<0.01) (Supplemental Table 2). Children were significantly more often diagnosed with the 
predominantly combined type of ADHD (77% vs. 51%; p<0.01) and used more frequent immediate 
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release psychostimulants (85% vs. 70%; p<0.01) in a higher dosage (0.6 vs. 0.5mg/kg/day; p=0.01) 
compared to adolescents. By definition, significant differences were observed in age, height, weight, 
and BMI. No differences were observed in height-sds, BMI-sds, or height velocity (Supplemental 
Table 3). 
Figure 2a shows the observed differences in BMI-sds after 18 months of psychostimulant treatment 
for the total population, for which a significant decrease was observed (p<0.01). In the normal 
weight, overweight, and obese subgroup a significant decrease was observed, but not in the 
underweight subgroup (Table 2). No significant differences were observed in change in BMI-sds 
between male and female participants (Supplemental Table 2). Children decreased significantly more 
in BMI-sds compared to adolescents (-0.5 vs. -0.3; p=0.03) (Supplemental Table 3). At T=18, 
significantly less participants were classified as overweight (14% vs. 21%) and obese (4% vs. 7%), and 
significantly more as underweight (14% vs. 5%). Four percent of the participants were classified in a 
higher BMI-subgroup at T=18. 
Figure 2. Box plots with median and interquartile ranges of (A) body mass index standard deviation 
score changes and (B) height standard deviation score changes during follow-up in children with 




A significant decrease in height-sds was observed in the total population and all subgroups, except 
the overweight subgroup (Figure 2b and Table 2). Females decreased significantly more in height-sds 
in comparison with males (-0.2 vs. -0.1; p=0.02) (Supplemental Table 2), and children decreased more 
in height-sds than adolescents (-0.2 vs. 0.0; p<0.01) (Supplemental Table 3). 
A significant increase in medication dosage (mg/kg/day) was noticed over the 18 month treatment 
period in the total population, and in the underweight, normal weight, and overweight subgroup, 
while in the obese subgroup no increase was shown (Table 2). No differences in dosage change were 
observed between males and females (Supplemental Table 2). In children the dosage increased 
significantly more than in adolescents (0.2 vs. 0.1; p<0.01) (Supplemental Table 3). 
In Figure 3 it is shown that psychostimulant dosage was weakly correlated with change in BMI-sds (r= 
-0.3 (-0.9 - -0.4); p<0.01), and height-sds (r= -0.2 (-0.5- -0.1); p=0.01). After adjustment for 
confounding factors (model BMI-sds change: baseline BMI-sds and type of methylphenidate; model 
height-sds change: age and type of methylphenidate) in a multivariable linear regression analyses the 
correlations did not change (BMI-sds r= -0.3 (-0.9 - 0.5); p<0.01), height-sds r= -0.2 (-0.4 - -0.1); 
p=0.01). 
Figure 3. Scatter dots representing the correlation between (A) body mass index standard deviation 
score and psychostimulant dosage (mg/kg/day) and (B) height standard deviation score and 












Table 2. BMI-sds, height-sds and medication dosage change after 18 months of psychostimulant treatment (n=298) 
 BMI-sds Height-sds Medication dosage (mg/kg/d) 
 T=0 T=18 P value T=0 T=18 P value T=0 T=18 P value 
All n=298 0.5 (-2.8-4.5) 0.0 (-3.4-4.1) <0.01 0.0 (-3.4-3.3) -0.2 (-3.6-3.7) <0.01 0.5 (0.2-1.4) 0.6 (0.1-1.8) <0.01 
UW n=16 -1.5 (-2.8- -1.2) -1.7 (-3.4- -0.8) 0.15 -0.2 (-1.5-1.0) -0.5 (-2.3-1.1) 0.03 0.6 (0.4-1.1) 0.8 (0.4-1.3) <0.01 
NW n=198 0.0 (-1.1-1.1) -0.3 (-2.1-2.3) <0.01 -0.2 (-3.4-2.9) -0.3 (-3.6-3.2) <0.01 0.6 (0.2-1.4) 0.6 (0.1-1.8) <0.01 
OW n=62 1.6 (1.1-2.3) 0.9 (-0.5-2.4) <0.01 0.3 (-2.2-3.3) 0.3 (-2.8-3.7) 0.61 0.5 (0.2-0.9) 0.6 (0.1-1.6) <0.01 
O n=22 2.9 (2.4-4.5) 2.3 (0.1-4.1) <0.01 0.2 (-1.3-2.2) 0.0 (-1.5-1.6) 0.01 0.5 (0.2-1.0) 0.5 (0.2-1.5) 0.27 
Data presented median with range. BMI = body mass index, sds = standard deviation score, UW = underweight, NW = normal weight, OW = overweight, O = 












Psychostimulants are suggested to be associated with weight reduction and growth suppression. As a 
result of which there is some restraint in the use of psychostimulants which may lead to a lower 
quality of life due to untreated symptoms [14,16,23-28]. However, literature is inconsistent and it is 
unknown whether the observed effects are dosage and/or BMI dependent, as BMI may be a 
reflection of the variability of ADHD symptoms. Therefore, this retrospective observational study 
evaluated the influence of psychostimulants on BMI-sds and height-sds over an 18 month treatment 
period and studied the correlation between psychostimulant dosage and BMI-sds and height-sds 
change.  
In the current study, a higher prevalence of overweight (21% vs. 9%) and obesity (7% vs. 3%) was 
observed at study start in comparison with the prevalence in the pediatric population of the 
Netherlands [35]. Although 72% of the study population was male, gender did not influence this 
observation as the prevalence of overweight/obesity in boys and girls is almost equal in the 
Netherlands [35]. The observed prevalence of overweight/obesity in our study is in line with other 
studies; however, it should be mentioned that there were differences in study designs [17,19,36,37]. 
One study included participants irrespectively of start of psychostimulant treatment [19]. Other 
studies collected their data through a telephone survey, were performed in a small population, or 
included only males or patients with ADHD of the predominantly combined type [36,37]. 
Consequently, a reliable comparison between studies is impossible.  
The prevalence of underweight in the current study was comparable with the prevalence in the 
pediatric population of the Netherlands [35]. However, another study performed in the Netherlands 
reported significantly less underweight in the ADHD population in comparison with the prevalence in 
the Netherlands [17]. This difference might be explained by the fact that they included only children 
of Caucasian descent with ADHD of the predominantly combined type. Since there was no studied 
population available to compare our study population with, we compared our analyzed participants 
with the excluded participants. Because these groups were comparable, it can be concluded that the 
observed prevalences are in concordance with the pediatric ADHD population of the Netherlands.  
Weight and target height reduction are assumed to be adverse effects of psychostimulant treatment. 
This assumption derived from the fact that psychostimulants increase the dopamine concentration at 
the synaptic space [38]. Dopamine inhibits gastric emptying and is therefore a well-known appetite 
reducer [39]. In addition, dopamine is suggested to inhibit growth hormone, which might cause 
growth retardation [22]. However literature is inconsistent on the actual effect upon this in daily 
clinical practice. In the current study, a reliable comparison between our results and the literature 
could not be performed due to differences in study populations (i.e., gender, age, and type of 
disease) [14,16,17], follow up period [15,18], and medication use [15,19]. In contrast to the studies 
mentioned above, our study focused on the effect of psychostimulants in the different BMI-
subgroups. In this study, a significant reduction in BMI-sds after 18 months of psychostimulant 
treatment was observed, which resulted in fewer participants classified as obese and/or overweight, 
and more as underweight. However, the decline in BMI-sds was not observed in the underweight 
subgroup, while they received the highest psychostimulant dosage (mg/kg/day). Furthermore, 4% of 
the participants were classified in a higher BMI subgroup at the end of the follow-up period. These 
observations along with the weak correlation between BMI-sds change and psychostimulant dosage 
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raises the question whether reduction in weight is actually caused by a reduction in appetite induced 
by psychostimulants. As stated before, a patient’s BMI may be a reflection of specific ADHD 
symptoms associated with weight gain. Reduction in BMI-sds may therefore be related to a reduction 
of ADHD symptoms rather than a side effect of psychostimulants, which was also suggested in 
previous studies [5-8]. This is underlined by the fact that the predominantly inattentive subtype of 
ADHD was more frequently diagnosed in the adolescent and underweight subgroup, in which smaller 
reductions in BMI-sds were observed. However, we can only speculate on this theory since the 
symptoms were not systematically reported.  
A significant decline in height-sds was observed in the total study population. Although the decline 
was significant, it was not observed in all subgroups and differences were rather small, which poses 
the question whether this observation is clinical relevant. However, it should be mentioned that the 
used dosage may have influenced this observation, as the subgroups with a lower dosage showed a 
slighter decline in height-sds. Especially, since it can be assumed that a higher dosage of 
psychostimulants leads to a higher dopamine availability which might result in a greater inhibition of 
growth hormone and thereby a more pronounced effect on growth [14,38]. Literature is inconsistent 
in the association between psychostimulants and target height reduction [22]. In addition, it has 
been suggested that the effect of psychostimulants on height attenuates over time and is thereby 
not affecting the target height [24-28]. This could be due to a feedback system resulting in an 
increase in dopamine receptors in the synaptic space, as a result of which the free dopamine levels 
returns to the normal level, as described in rats [22]. Consequently growth hormone is inhibited only 
temporarily and has thereby no consistent effect on height velocity and therefore not affecting the 
target height [22]. We were not able to study the effect on target height, since our participants did 
not reach their final height during the study period. However, height velocity was within the normal 
range in all subgroups [40], and only a weak correlation was observed between psychostimulant 
dosage and change in height-sds. These findings suggest that the decline in height-sds is not related 
to psychostimulants, but physiological due to normal variation of growth in height and support the 
previously mentioned theory. In addition, height velocity is related to nutritional status with 
reversible growth retardation in underweight and relative growth acceleration in overweight/obesity 
[22]. 
In this population-based study, the effect of psychostimulant dosage on BMI-sds and height-sds was 
systematically evaluated in ADHD patients during a follow-up period up to 18 months. In contrast to 
previous studies, our study focused on the effect of psychostimulants dosage in different BMI-
subgroups. Moreover, only naive patients for psychostimulants without additional psychiatric 
medication were included, whereby bias due to previous pharmacologically ADHD treatment was 
excluded. However, certain limitations due to the retrospective study design must be considered. 
First, no controls without psychostimulant treatment were included, since these patients do not have 
a follow-up at pediatric outpatient clinics in the Netherlands. However, as it may be assumed that 
children grow according their own percentile during normal development, height-sds and BMI-sds 
can be used to evaluate changes in growth over time. In addition, only patients who started with 
methylphenidate were included, since amphetamines are in general prescribed by a pediatric 
psychiatrist and not by a general pediatrician. Therefore, no statements could be made on the 
influence of amphetamines on weight and height change. Prevalent comorbidities such as depression 
and conduct disorder could not be taken into account as potential confounder, since these patients 
are mainly treated at (pediatric) psychiatric clinics in the Netherlands. Furthermore, relatively many 
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participants were excluded for analysis. Some participants were lost to follow up and others were 
referred to specialized (pediatric) psychiatric clinics or followed up by the general practitioner. 
However, as stated before characteristics of participants excluded for analysed were not significantly 
different from those analysed. Therefore, results were most likely not affected by the participants 
lost to follow-up, and thus applicable for the entire pediatric ADHD population of the Netherlands. 
Since symptoms of ADHD were not systematically recorded in medical files, we could not objectify 
whether medication dosage was adjusted according to symptomatology. In addition, we could not 
determine which symptoms might play a role in any change in BMI-sds. Finally, our results might 
have been influenced by the fact that methylphenidate tablets are only available in fixed dosages, 
affecting the prescribed dosage in mg/kg/day. This could also explain the relatively lower dosage in 
the overweight and obesity subgroups. Since many patients are restrained to use multiple tablets to 
achieve a dosage comparable with other weight categories, especially due to the fear for reduction in 
appetite and concerns about target height. Impact of above factors on the results cannot be ruled 
out. Therefore, further studies on the etiology of BMI-change are warranted. Focus on the ADHD 
symptoms seems to be of particularly relevance. 
 
Conclusion 
After 18 months of psychostimulant treatment a significant decline in BMI-sds and height-sds was 
observed. However, the correlation with medication dosage was weak and the decline was not 
observed in all subgroups. Therefore, further studies into the etiology of BMI-change are warranted, 
particularly with regard to the ADHD symptoms. 
 
Clinical significance 
Psychostimulant treatment in patients with ADHD is associated with weight reduction and growth 
retardation, as a result of which there is some restraint in the use which may lead to a reduction in 
quality of life. However, reports in literature are inconsistent. Since BMI might be a reflection of the 
variability of ADHD symptoms, we focused on the effect of psychostimulants dosage in different BMI-
subgroups. Our data showed that weight reduction and growth retardation were not observed in all 
BMI-subgroups, and were only weakly correlated with psychostimulant dosage. This may imply that 
psychostimulants are not the primary cause of weight reduction and growth retardation, and 
therefore safe to use and the fear for side effects can be waived. In conclusion, further studies into 
the etiology of weight reduction and growth retardation are warranted, particularly with regard to 
the reduction in ADHD symptoms. 
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Supplementary Table 1. Baseline characteristics of patients excluded versus included for analysis 
 Included n=558 Not analysed n=260 Analysed n=298 P-value 
Age (yr) 9.4 (4.2-17.7) 10.4 (4.2-17.7) 9.8 (4.5-17.6) 0.08 
Male n (%) 407 (73) 192 (74) 215 (72) 0.65 
Height (cm) 143.8 (99.8-193.6) 145.4 (105.4-193.6) 142.2 (99.8-189.7) 0.07 
Height-sds 0.0 (-3.5-3.3) 0.0 (-3.5-2.8) 0.0 (-3.4-3.3) 0.78 
Weight (kg) 38.0 (15.3-113.4) 39.8 (15.3-113.4) 36.6 (16.5-84.9) 0.06 
BMI (kg/m²) 17.7 (12.9-36.9) 17.9 (13.1-36.9) 17.6 (12.9-31.2) 0.17 
BMI-sds 0.5 (-2.8-4.5) 0.5 (-2.2-4.4) 0.5 (-2.8-4.5) 0.59 
- Underweight 36 (7) 20 (8) 16 (5) 0.64 
- Normal weight 371 (67) 173 (67) 198 (66)  
- Overweight 109 (20) 47 (18) 62 (21)  
- Obesity 42 (8) 20 (8) 22 (7)  
Type disease n (%)   0.18 
- Combined 379 (68) 184 (71) 195 (65)  
- Inattentive 179 (22) 76 (29) 103 (35)  
Methylphenidate n (%)   0.13 
- SA 426 (77) 191 (74) 235 (79)  
- LA 132 (24) 69 (27) 63 (21)  
Dosage (mg/kg/d) 0.5 (0.1-1.4) 0.5 (0.1-1.4) 0.5 (0.2-1.4) 0.65 
Data presented as number (%) or median with range. BMI = body mass index, sds = standard 
deviation score,  SA = short acting, LA = long acting. P-values for Kruskal-wallis test (continuous data) 














Supplementary Table 2. Baseline characteristics and changes in growth parameters and dosage after 
18 months of treatment of the total analyzed population, stratified by gender (n=298) 
 Male n=215 Female n=83 P-value 
Baseline characteristics   
Age (yr) 9.7 (4.5-17.6) 9.6 (4.2-17.6) 0.51 
Height (cm) 142.4 (99.8-189.7) 139.8 (103.6-173.0) 0.19 
Height-sds 0.0 (-3.4-2.9) 0.0 (-2.5-3.3) 0.97 
Height velocity (cm/year) 6.5 (0.3-15.7) 5.2 (0.1-12.0) <0.01 
Weight (kg) 36.5 (17.7-84.9) 35.4 (16.5-63.7) 0.46 
BMI (kg/m²) 17.4 (12.9-27.4) 17.6 (13.1-31.2) 0.64 
BMI-sds 0.5 (-2.8-3.5) 0.5 (-2.8-4.5) 0.66 
- Underweight 9 (4) 7 (8) 0.21 
- Normal weight 144 (67) 54 (65)  
- Overweight 43 (20) 19 (23)  
- Obesity 19 (9) 3 (4)  
Type disease n (%)  <0.01 
- Combined 152 (71) 43 (52)  
- Inattentive 63 (29) 40 (48)  
Methylphenidate n (%)  0.27 
- IR 173 (80) 62 (75)  
- SR 42 (20) 21 (25)  
Dosage (mg/kg/d) 0.6 (0.1-1.4) 0.5 (0.2-1.1) 0.60 
    
Changes after 18 months of treatment   
ΔBMI-sds -0.4 (-2.4-1.5) -0.5 (-2.2-0.8) 0.45 
ΔHeight-sds -0.1 (-0.9-1.3) -0.2 (-1.7-1.3) 0.02 
ΔDosage (mg/kg/d) 0.1 (-0.6-1.3) 0.1 (-0.4-0.7) 0.21 
Data presented as number (%) or median with range. BMI = body mass index, sds = standard 
deviation score, IR = immediate release, SR = sustained release. P-values for student’s t test 












Supplementary Table 3. Baseline characteristics and changes in growth parameters and dosage after 
18 months of treatment of the total analysed population, stratified by age (n=298) 
 Children n=179 Adolescents n=119 P-value 
Baseline characteristics   
Age (yr) 8.1 (4.5-9.9) 12.1 (10.0-17.6) <0.01 
Male n (%) 124 (69) 91 (77) 0.18 
Height (cm) 132.1 (99.8-160.0) 156.0 (131.8-189.7) <0.01 
Height-sds 0.0 (-2.5-3.3) 0.1 (-3.4-2.2) 0.70 
Height velocity (cm/year) 6.0 (2.1-15.7) 6.2 (0.1-15.5) 0.543 
Weight (kg) 29.4 (16.5-51.5) 46.4 (25.5-84.9) <0.01 
BMI (kg/m²) 16.7(13.1-31.2) 18.7 (12.9-27.4) <0.01 
BMI-sds 0.5 (-2.1-4.5) 0.5 (-2.8-3.5) 0.77 
- Underweight 7 (4) 9 (8) 0.49 
- Normal weight 120 (67) 78 (66)  
- Overweight 37 (21) 25 (21)  
- Obesity 15 (8) 7 (6)  
Type disease n (%)  <0.01 
- Combined 137 (76) 61 (51)  
- Inattentive 42 (24) 58 (49)  
Methylphenidate n (%)  <0.01 
- IR 152 (85) 83 (70)  
- SR 27 (15) 36 (30)  
Dosage (mg/kg/d) 0.6 (0.2-1.2) 0.5 (0.2-1.4) 0.01 
    
Changes after 18 months of treatment   
ΔBMI-sds -0.5 (-2.4-1.5) -0.3 (-2.1-1.4) 0.03 
ΔHeight-sds -0.2 (-1.8-0.9) 0.0 (-0.9-1.3) <0.01 
ΔDosage (mg/kg/d) 0.2 (-0.6-1.3) 0.1 (-0.3-0.6) 0.01 
Data presented as number (%) or median with range. BMI = body mass index, sds = standard 
deviation score. IR= immediate release, SR = sustained release. P-values for student’s test 
(continuous data) and χ2 test (categorical data). 
 
 
 
 
